Janux Therapeutics Q3 2026 Earnings Date & Estimates

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biopharmaceutical company based in San Diego, California, developing cancer immunotherapies designed to activate the immune system selectively within the tumor microenvironment. The company’s technology is intended to direct T cells toward cancer cells while limiting activation in healthy tissues.

Janux’s core technology platform, known as TRACTr, uses conditionally activated T-cell engager molecules designed to remain masked in circulation and become activated by proteases that are more prevalent in tumors. The platform is being applied to develop treatments for solid tumors, an area where safety and the tumor’s immunosuppressive environment can limit existing immunotherapy approaches.

The company’s investigational pipeline includes JANX007, a prostate-specific membrane antigen (PSMA)-directed T-cell engager being studied in prostate cancer, and JANX008, an epidermal growth factor receptor (EGFR)-directed program being evaluated for solid tumors. Janux conducts its research and clinical development activities primarily through operations in the United States and has advanced its programs through clinical trials rather than commercial product sales.